Alpha Biopharma (Jiangsu) Co., Ltd.   Report issue

For profit Phase 3
Founded: Jiangsu China (2006)
Status: Left NME R&D (2023)

Organization Overview

First Clinical Trial
2018
NCT03653546
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Alpha Biopharma (Jiangsu) Co., Ltd.

Active Ingredients

Drugs in Phase 3 Trials (3)

azd3759 (1 trial)

erlotinib (tarceva) (1 trial)

gefitinib (iressa) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Neoplasm Metastasis (Phase 3)

Neoplasms, Second Primary (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 3